Verrica Pharmaceuticals Inc
NASDAQ:VRCA

Watchlist Manager
Verrica Pharmaceuticals Inc Logo
Verrica Pharmaceuticals Inc
NASDAQ:VRCA
Watchlist
Price: 7.13 USD -0.7% Market Closed
Market Cap: $114m

Operating Margin

-53.2%
Current
Improving
by 596.2%
vs 3-y average of -649.4%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-53.2%
=
Operating Income
$-16.4m
/
Revenue
$30.8m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-53.2%
=
Operating Income
$-16.4m
/
Revenue
$30.8m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Verrica Pharmaceuticals Inc
NASDAQ:VRCA
114m USD
Loading...
US
Eli Lilly and Co
NYSE:LLY
972.2B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
547.5B USD
Loading...
CH
Roche Holding AG
SIX:ROG
275.9B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
208.8B GBP
Loading...
CH
Novartis AG
SIX:NOVN
219.3B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
272.1B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
148.3B USD
Loading...
FR
Sanofi SA
PAR:SAN
94.2B EUR
Loading...

Market Distribution

Lower than 82% of companies in the United States of America
Percentile
18th
Based on 14 112 companies
18th percentile
-53.2%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Verrica Pharmaceuticals Inc
Glance View

Verrica Pharmaceuticals, Inc. engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. The company is headquartered in West Chester, Pennsylvania and currently employs 38 full-time employees. The company went IPO on 2018-06-15. The firm is focused on developing and commercializing treatments for skin diseases. The firm's lead product candidate, VP-102, is a drug-device combination of its topical solution of cantharidin, a widely recognized, naturally sourced agent to treat topical dermatological conditions, administered through its single-use precision applicator. The company is developing VP-102 for the treatment of molluscum contagiosum (molluscum), a highly contagious and primarily pediatric viral skin disease, external genital warts and common warts. The company also intends to develop its second cantharidin-based product candidate, VP-103, for the treatment of plantar warts, which are warts located on the bottom of the foot. The company also intends to develop its third product candidate, LTX-315, for the treatment of dermatological oncology indications, including non-metastatic melanoma and non-metastatic Merkel cell carcinoma.

VRCA Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-53.2%
=
Operating Income
$-16.4m
/
Revenue
$30.8m
What is Verrica Pharmaceuticals Inc's current Operating Margin?

The current Operating Margin for Verrica Pharmaceuticals Inc is -53.2%, which is above its 3-year median of -649.4%.

How has Operating Margin changed over time?

Over the last 3 years, Verrica Pharmaceuticals Inc’s Operating Margin has increased from -262.8% to -53.2%. During this period, it reached a low of -1 521.5% on Sep 30, 2023 and a high of -53.2% on Sep 30, 2025.

Back to Top